Logo

The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

Share this

The US FDA Approves Kyprolis (carfilzomib) + Darzalex (daratumumab) + Dexamethasone in Two Dosing Regimens for R/R Multiple Myeloma

Shots:

  • The US FDA has approved Janssen’s Darzalex + Amgen’s Kyprolis (carfilzomib) and dexamethasone (DKd)  in two dosing regimen (70 mg/m2 - qw and 56 mg/m2 - q2w) for the treatment of adult patients with r/r MM who have received 1-3L therapies
  • The approval of q2w dosing regimen is based on P-III CANDOR study assessing DKd (q2w) vs Kd in 466 patients with r/r MM and has met its 1EPs of PFS after a median follow-up of 16.9 & 16.3 mos. respectively
  • The inclusion of carfilzomib (qw) as an approved DKd regimen is based P-Ib EQUULEUS study assessing Darzalex in combination with multiple treatment regimens. Carfilzomib (qw) was evaluated with a starting dose of 20 mg/m2- which was increased to 70 mg/m2 on Cycle 1- Day 8 and onward

Source 1- Source 2 ­ Ref: Janssen- Amgen  | Image: Revlimid

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions